Physician profile
Todd D Eisner
NPI 1255303152
$3,633.72
in general payments reported to CMS, 2019-2025
26 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $417 · 2021: $188 · 2022: $156 · 2023: $325 · 2024: $1,068 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.72 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.11 | 2019-2025 | |
| Janssen Biotech, INC. | $525.73 | 2019-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $304.55 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.06 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $168.80 | 2020-2025 | General - Gi Dilatation, General - Polypectomy |
| Celgene Corporation | $158.19 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $149.36 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $145.67 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $126.00 | 2024-2025 | Entyvio |
| Madrigal Pharmaceuticals | $92.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $79.11 | 2020-2024 | Linzess |
| Aimmune Therapeutics, INC. | $78.68 | 2024-2025 | Zenpep |
| Shionogi INC | $78.56 | 2019 | |
| Merck Sharp & Dohme LLC | $67.29 | 2019 | |
| Erbe USA INC | $65.00 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $61.59 | 2019 | |
| Nestle Healthcare Nutrition INC. | $59.56 | 2023 | |
| Redhill Biopharma INC. | $55.48 | 2020-2021 | |
| Axonics, INC. | $49.79 | 2024 | Axonics |
| Ardelyx, INC. | $43.07 | 2024-2025 | Ibsrela |
| Vivus LLC | $33.80 | 2024-2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $32.16 | 2025 | Iqirvo |
| Amgen INC. | $22.49 | 2022 | |
| Shire North American Group INC | $19.59 | 2019 | |
| Alfasigma USA, INC. | $17.20 | 2020 | |
| Qol Medical, LLC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Eisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.